{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:13:08Z","timestamp":1748491988103,"version":"3.41.0"},"reference-count":49,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n      Die Positronenemissionstomografie\/Computertomografie mit prostataspezifischen Membranantigenen (PSMA-PET\/CT) findet zunehmende Anwendung in der Diagnostik des Prostatakarzinoms.\n      <\/jats:p><jats:p>\n     Ziel dieses Reviews ist die Darstellung und Bewertung etablierter und innovativer Indikationen f\u00fcr die PSMA-PET\/CT-Bildgebung.\n      <\/jats:p><jats:p>\n       Hintergrundwissen zur PSMA-PET\/CT und behandlungsrelevante Leitlinienempfehlungen werden veranschaulicht und durch aktuelle Studienergebnisse erg\u00e4nzt.\n      <\/jats:p><jats:p>\n    Die PSMA-PET\/CT zeigt sich der konventionellen Bildgebung \u00fcberlegen und kann in allen Stadien des Prostatakarzinoms je nach Indikation komplement\u00e4r oder substitutiv eingesetzt werden. Sie bietet Vorteile in Form eines reduzierten Zeitaufwands und einer geringeren Strahlenbelastung. Der Einsatz der PSMA-PET\/CT erm\u00f6glicht eine verbesserte Einsch\u00e4tzung des Krankheitsstatus und eine optimierte Therapieplanung. Ihre Anwendung erstreckt sich dabei vom initialen Karzinomverdacht \u00fcber Diagnose und Staging bis hin zur Therapieplanung beim biochemischen Rezidiv und metastasiertem Prostatakarzinom. Derzeit fehlen jedoch Belege f\u00fcr den prognostischen Wert PSMA-PET\/CT-basierter Therapieentscheidungen.\n      <\/jats:p><jats:p>\n    Die PSMA-PET\/CT bietet einen signifikanten diagnostischen und therapeutischen Mehrwert f\u00fcr viele Prostatakarzinompatienten. Ihr Einsatz unterst\u00fctzt die Evaluierung m\u00f6glicher Intensivierungs- oder Deeskalationsstrategien und erm\u00f6glicht so eine personalisierte Therapieplanung.\n      <\/jats:p>","DOI":"10.1055\/a-2523-5885","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:21:46Z","timestamp":1742343706000},"page":"263-270","source":"Crossref","is-referenced-by-count":0,"title":["Indikationen zur Durchf\u00fchrung der PSMA-PET-CT im Rahmen der Prostatakarzinomdiagnostik"],"prefix":"10.1055","volume":"56","author":[{"given":"Philipp","family":"Krausewitz","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1148\/radiol.2017172607","article-title":"(68)Ga Prostate-specific Membrane Antigen PET\/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging","volume":"287","author":"E Lopci","year":"2018","journal-title":"Radiology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.juro.2018.01.079","article-title":"(68)Ga-PSMA Positron Emission Tomography\/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study","volume":"200","author":"E Lopci","year":"2018","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study","volume":"80","author":"L Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eururo.2021.11.019","article-title":"Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography","volume":"82","author":"VH Meissner","year":"2022","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/cancers15041266","article-title":"Radical Prostatectomy without Prior Biopsy in Patients with High Suspicion of Prostate Cancer Based on Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography: A Prospective Cohort Study","volume":"15","author":"M Chaloupka","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13063-023-07197-0","article-title":"DEPROMP Trial: the additive value of PSMA-PET\/CT-guided biopsy for prostate cancer management in biopsy na\u00efve men-study protocol for a randomized trial","volume":"24","author":"P Krausewitz","year":"2023","journal-title":"Trials"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s11548-015-1233-y","article-title":"Multimodal image-guided prostate fusion biopsy based on automatic deformable registration","volume":"10","author":"O Zettinig","year":"2015","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eucr.2017.05.006","article-title":"Targeted Prostate Biopsy Using (68)Gallium PSMA-PET\/CT for Image Guidance","volume":"14","author":"DN Simopoulos","year":"2017","journal-title":"Urol Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"(68)Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study","volume":"48","author":"L-L Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","volume":"5","author":"T Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"MS Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis","volume":"84","author":"KM Chow","year":"2023","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial","volume":"63","author":"I Sonni","year":"2022","journal-title":"J Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euros.2023.12.001","article-title":"The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer","volume":"59","author":"WI Luining","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"WP Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","article-title":"Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard","volume":"5","author":"A Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1097\/JU.0000000000001596","article-title":"Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study","volume":"205","author":"T Amiel","year":"2021","journal-title":"J Urol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"16708","DOI":"10.1038\/s41598-018-35058-3","article-title":"Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET\/CT imaging features in primary prostate cancer","volume":"8","author":"C Kesch","year":"2018","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bju.14858","article-title":"Detection and localisation of primary prostate cancer using (68) gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology","volume":"126","author":"AA Kalapara","year":"2020","journal-title":"BJU Int"},{"key":"ref20","first-page":"P1241","article-title":"PSMA PET\/CT for prostate cancer patients after focal therapy: a single center retrospective analysis","volume":"64","author":"M Jafarvand","year":"2023","journal-title":"J Nucl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/1754-9485.12988","article-title":"Utility of Ga(68) prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort","volume":"64","author":"GP Tarr","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00259-019-04568-1","article-title":"Impact of (68)Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer","volume":"47","author":"DA Ferraro","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13014-016-0646-2","article-title":"Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study","volume":"11","author":"S Dewes","year":"2016","journal-title":"Radiat Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","article-title":"PSMA-PET\/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial","volume":"116","author":"C Petit","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2024","volume":"79","author":"P Cornford","year":"2022","journal-title":"Eur Urol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2967\/jnumed.118.222885","article-title":"Bridging the Imaging Gap: PSMA PET\/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature","volume":"60","author":"\u00d6 Ekmekcioglu","year":"2019","journal-title":"J Nucl Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The Impact of (68)Ga-PSMA PET\/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study","volume":"59","author":"PJ Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"26","author":"A Pozdnyakov","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"SJ Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1200\/JCO.2023.41.16_suppl.5091","article-title":"PSMA PET findings in an \u201cEMBARK-like\u201d cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis","volume":"41","author":"WR Armstrong","year":"2023","journal-title":"JCO"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease","volume":"62","author":"F Barbato","year":"2021","journal-title":"J Nucl Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"M Perera","year":"2020","journal-title":"Eur Urol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"R Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"E Francini","year":"2018","journal-title":"Prostate"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"CJ Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"K Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer","volume":"68","author":"G Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jmri.27485","article-title":"Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions","volume":"55","author":"S van Nieuwenhove","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data","volume":"43","author":"S Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ph10030068","article-title":"Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between (99m)Tc-Bone-Scintigraphy and (68)GaGa-PSMA PET\/CT","volume":"10","author":"L Thomas","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume","volume":"9","author":"B Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer","volume":"25","author":"WP Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy","volume":"10","author":"R Seifert","year":"2020","journal-title":"Theranostics"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.semnuclmed.2023.06.003","article-title":"PSMA PET\/CT for Response Assessment of (177)Lu-PSMA Therapy","volume":"54","author":"PE Hartrampf","year":"2024","journal-title":"Seminars in Nuclear Medicine"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"AK Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"B Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.122.264489","article-title":"Prognostic Value of Tumor Volume Assessment on PSMA PET After (177)Lu-PSMA Radioligand Therapy Evaluated by PSMA PET\/CT Consensus Statement and RECIP 1.0","volume":"64","author":"F Kind","year":"2023","journal-title":"J Nucl Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","article-title":"Initial Experience with Volumetric (68)Ga-PSMA I&T PET\/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer","volume":"58","author":"S Schmuck","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2523-5885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:12:06Z","timestamp":1748473926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2523-5885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":49,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2523-5885","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}